EGFR and cancer: If both autophagy inhibitors and inducers can be useful in combination with EGFR TKIs in treating EGFR-driven NSCLC tumours, it must be concluded that another regulatory process upstream of autophagy must be responsible, at least in part, for some cancer cells to be more dependent on autophagy than others.